Boston Scientific Stock In Shambles: Down -17% With 5-Day Losing Streak
Boston Scientific (BSX) – a developer and manufacturer of interventional medical devices – hit a 5-day losing streak, with cumulative losses over this period amounting to -17%. The company’s market cap has crashed by about $15 Bil over the last 5 days and currently stands at $71 Bil.
Is this an opportunity or a trap? There are only a couple of things to fear in BSX stock given its overall Strong operating performance and financial condition. Considering stock’s Moderate valuation, we think it is Attractive (For details, see Buy or Sell BSX).
But here is the interesting part. You are reading about this -17% move after it happened. The market has already priced in the news. To manage individual stock risk before the headlines, you need predictive signals, not notifications. High Quality Portfolio has a risk model designed to manage stock-specific drawdowns better.
Returns vs S&P 500
- Boston Scientific Stock Hits Key Support – Buying Opportunity?
- BSX Stock: Don’t Try To Catch The Falling Knife
- Time To Buy The Dip In Boston Scientific Stock?
- How Low Can BSX Really Go In A Market Crash?
- Is BSX Stock A Value Trap Or A Rebound Play?
- Stronger Bet Than IDEXX Laboratories Stock: DXCM, BSX Deliver More
The following table summarizes the return for BSX stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | BSX | S&P 500 |
|---|---|---|
| 1D | -0.7% | 0.3% |
| 5D (Current Streak) | -17.0% | 1.7% |
| 1M (21D) | -16.7% | 5.4% |
| 3M (63D) | -37.1% | 10.4% |
| YTD 2026 | -49.7% | 11.0% |
| 2025 | 6.8% | 16.4% |
| 2024 | 54.5% | 23.3% |
| 2023 | 24.9% | 24.2% |
Take a look at what history tells you about whether past dips like this have been buying opportunities or traps: BSX Dip Buyer Analysis.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 72 S&P constituents with 3 days or more of consecutive gains and 125 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 30 | 52 |
| 4D | 21 | 35 |
| 5D | 7 | 28 |
| 6D | 5 | 5 |
| 7D or more | 9 | 5 |
| Total >=3 D | 72 | 125 |
Key Financials for Boston Scientific (BSX)
Last 2 Fiscal Years:
| Metric | FY2024 | FY2025 |
|---|---|---|
| Revenues | $16.7 Bil | $20.1 Bil |
| Operating Income | $3.0 Bil | $4.0 Bil |
| Net Income | $1.9 Bil | $2.9 Bil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ4 | 2026 FQ1 |
|---|---|---|
| Revenues | $5.3 Bil | $5.2 Bil |
| Operating Income | $1.0 Bil | $1.1 Bil |
| Net Income | $672.0 Mil | $1.3 Bil |
The losing streak BSX stock is currently on doesn’t inspire much confidence among investors. In contrast, Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.